Cholestatic Liver Disease Overlap Syndromes

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 243-253

  Mayo, Marlyn J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Autoimmune hepatitis; Biliary cirrhosis; Overlap; Sclerosing cholangitis; Variant

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUDESONIDE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; HYDRALAZINE; IMMUNOGLOBULIN G4; INFLIXIMAB; METHYLDOPA; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; NITROFURANTOIN; OXYPHENISATINE; PREDNISONE; RITUXIMAB; SMOOTH MUSCLE ANTIBODY; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOGLOBULIN G DEFICIENCY; LIVER BIOPSY; LIVER HISTOLOGY; MONOTHERAPY; OVERLAP SYNDROME; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SYNDROME CREST; TOXIC HEPATITIS;

CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; SYNDROME;

EID: 84875620007     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.12.006     Document Type: Review

References (40)

1. Czaja A.J., Muratori P., Muratori L., et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004, 24(4):322-329.
2. O'Brien C., Joshi S., Feld J.J., et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008, 48(2):550-556.
3. Lindor K.D., Gershwin M.E., Poupon R., et al. Primary biliary cirrhosis. Hepatology 2009, 50(1):291-308.
4. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis 2003, 7(4):865-878.
5. Degott C., Zafrani E.S., Callard P., et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999, 29(4):1007-1012.
6. Talwalkar J.A., Keach J.C., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002, 97(5):1191-1197.
7. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51(2):237-267.
8. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31(5):929-938.
9. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54(2):374-385.
10. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48(1):169-176.
11. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28(2):296-301.
12. Muratori L., Cassani F., Pappas G., et al. The hepatitic/cholestatic " overlap" syndrome: an Italian experience. Autoimmunity 2002, 35(8):565-568.
13. Gatselis N.K., Zachou K., Papamichalis P., et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. Dig Liver Dis 2010, 42(11):807-812.
14. Boberg K.M., Fausa O., Haaland T., et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996, 23(6):1369-1376.
15. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33(4):537-542.
16. van Buuren H.R., van Hoogstraten H.J.E., Terkivatan T., et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000, 33(4):543-548.
17. Olsson R., Glaumann H., Almer S., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20(2):190-196.
18. Lewin M., Vilgrain V., Ozenne V., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009, 50(2):528-537.
19. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47(3):949-957.
20. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33(3):544-553.
21. Zen Y., Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010, 34(12):1812-1819.
22. Naitoh I., Zen Y., Nakazawa T., et al. Small bile duct involvement in IgG4-related sclerosing cholangitis: liver biopsy and cholangiography correlation. J Gastroenterol 2011, 46(2):269-276.
23. Alswat K., Al-Harthy N., Mazrani W., et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012, 107(1):56-63.
24. Umemura T., Zen Y., Hamano H., et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 2011, 46(Suppl 1):48-55.
25. Khosroshahi A., Bloch D.B., Deshpande V., et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010, 62(6):1755-1762.
26. van Casteren-Messidoro C., Prins G., van Tilburg A., et al. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis 2012, 6(5):630-631.
27. Subramaniam K., Chitturi S., Brown M., et al. Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate. Inflamm Bowel Dis 2011, 17(11):E149-E150.
28. Goldfeld D.A., Verna E.C., Lefkowitch J., et al. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. Dig Dis Sci 2011, 56(11):3386-3388.
29. Ozorio G., McGarity B., Bak H., et al. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007, 187(9):524-526.
30. Joshi S., Cauch-Dudek K., Wanless I.R., et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002, 35(2):409-413.
31. Silveira M.G., Talwalkar J.A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102(6):1244-1250.
32. Czaja A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998, 28(2):360-365.
33. Lohse A.W., zum Buschenfelde K.H., Franz B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29(4):1078-1084.
34. Chazouilleres O., Wendum D., Serfaty L., et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006, 44(2):400-406.
35. Wu C.H., Wang Q.H., Tian G.S., et al. Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study. Chin Med J (Engl) 2006, 119(3):238-241.
36. Rabahi N., Chretien Y., Gaouar F., et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010, 34(4-5):283-287.
37. Talwalkar J.A., Angulo P., Keach J.C., et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005, 39(2):168-171.
38. Boberg K.M., Egeland T., Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38(9):991-995.
39. Al-Chalabi T., Portmann B.C., Bernal W., et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008, 28(2):209-220.
40. Luth S., Kanzler S., Frenzel C., et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009, 43(1):75-80.